We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

152 hedge funds and large institutions have $1.24B invested in Achillion Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more call options, than puts

Call options by funds: $41.9M | Put options by funds: $17.2M

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

50% more capital invested

Capital invested by funds: $829M → $1.24B (+$415M)

8% more funds holding

Funds holding: 141152 (+11)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

4% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 49

Holders
152
Holders Change
+11
Holders Change %
+7.8%
% of All Funds
3.99%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
31
Increased
47
Reduced
49
Closed
18
Calls
$41.9M
Puts
$17.2M
Net Calls
+$24.7M
Net Calls Change
+$10.4M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$121M -$4.64M -510,922 -4%
O
2
OrbiMed
New York
$104M +$40.2M +4,427,400 +85%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$96.8M -$7.32M -805,410 -8%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$95.7M
Vanguard Group
5
Vanguard Group
Pennsylvania
$82.9M +$2.83M +311,482 +4%
JHIU
6
Janus Henderson Investors US
Colorado
$75.7M -$2.88M -317,083 -4%
Millennium Management
7
Millennium Management
New York
$52.7M +$41.3M +4,548,098 +1,369%
BFA
8
BlackRock Fund Advisors
California
$48.2M -$2.29M -252,325 -5%
State Street
9
State Street
Massachusetts
$44.7M -$7.79M -856,518 -17%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$43.8M +$108K +11,900 +0.3%
Wellington Management Group
11
Wellington Management Group
Massachusetts
$34.8M -$69.5M -7,647,125 -70%
BIT
12
BlackRock Institutional Trust
California
$31.5M +$816K +89,770 +3%
Goldman Sachs
13
Goldman Sachs
New York
$28.4M +$3.25M +358,020 +16%
BBA
14
Baker Bros. Advisors
New York
$21.6M
RI
15
RTW Investments
New York
$21.5M -$5.46M -600,904 -23%
DM
16
Deerfield Management
New York
$18M
EAM
17
EverPoint Asset Management
Connecticut
$17.3M -$8.18M -900,000 -36%
Deutsche Bank
18
Deutsche Bank
Germany
$15.3M +$6.45M +709,723 +100%
Northern Trust
19
Northern Trust
Illinois
$14.7M -$20.5K -2,259 -0.2%
BB
20
BB Biotech
Switzerland
$13.8M
Connor, Clark & Lunn Investment Management (CC&L)
21
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$13.7M +$2.79M +306,900 +32%
Invesco
22
Invesco
Georgia
$12.2M +$10.1M +1,114,785 +9,557%
JP Morgan Chase
23
JP Morgan Chase
New York
$11.9M -$130K -14,320 -1%
RSCM
24
Rock Springs Capital Management
Maryland
$11.9M -$182K -20,000 -2%
Axa
25
Axa
France
$10.6M -$278K -30,563 -3%

ACHN Hedge Fund Activity: Q4 2015 in Review

152 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2015, worth a combined $1.24B — up 50% from $829M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ACHN positions and 18 closed out — a net gain of 13 holders — while 47 added to existing stakes and 49 trimmed.

The largest buyer was Millennium Management, adding an estimated $41.3M. The largest seller was Wellington Management Group, cutting an estimated $69.5M.

  • 152 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2015, up from 141 in Q3 2015.
  • Funds reported $1.24B of Achillion Pharmaceuticals stock for Q4 2015, up 50% quarter-over-quarter.
  • 31 funds opened new Achillion Pharmaceuticals positions in Q4 2015 and 18 closed out, a net change of +13 holders.
  • The largest Achillion Pharmaceuticals buyer in Q4 2015 was Millennium Management, an estimated $41.3M added.
  • The largest Achillion Pharmaceuticals seller in Q4 2015 was Wellington Management Group, an estimated $69.5M sold.

Based on aggregated 13F filings for Q4 2015.